A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial

Authors:
  • ABAdrian Bibby
    Adrian Bibby
  • RFRichard Foster
    Richard Foster

Abstract
The calcipotriene/betamethasone dipropionate two‐compound scalp formulation has been shown to be safe and effective in the treatment of scalp psoriasis over 8 weeks, but the patients studied were mainly White and non‐Hispanic. The aim of this study was to evaluate the efficacy and safety of the two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients. A total of 99 Hispanic/Latino and 78 Black/African American patients were randomized double‐blind in a 3 : 1 ratio to 8 weeks of once daily treatment of scalp psoriasis with either the two‐compound scalp formulation (n = 135) or its vehicle (n = 42). In the two‐compound group, 71.9% of patients had cleared or minimal disease at week 8 by the investigator’s global assessment compared to 40.5% in the vehicle group (odds ratio 3.30; 95% CI 1.62–6.72; P < 0.001). For the five secondary efficacy response criteria, three (total sign score, thickness of scalp psoriasis, patient’s global assessment) showed that two‐compound scalp formulation was statistically significantly more effective than its vehicle, and the other two (redness and scaliness of scalp psoriasis) approached statistical significance in favor of the two‐compound scalp formulation. There was no statistically significant difference (P = 1.00) between the percentage of patients with adverse reactions in the two‐compound group (7.0%) and the vehicle group (7.9%). The two‐compound scalp formulation is safe and effective in the treatment of scalp psoriasis over 8 weeks in Hispanic/Latino and Black/African American patients.

This publication has 8 references indexed in Scilit: